---
title: Effect of Two Different Doses of Neostigmine on the Gastric Residual Volume and Aspiration in Critically Ill Patients
nct_id: NCT06687187
overall_status: COMPLETED
sponsor: Zulekha Hospitals
study_type: OBSERVATIONAL
primary_condition: Gastric Reflux
countries: Egypt
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06687187.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06687187"
ct_last_update_post_date: 2024-11-13
last_seen_at: "2026-05-12T07:25:50.385Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Effect of Two Different Doses of Neostigmine on the Gastric Residual Volume and Aspiration in Critically Ill Patients

**Official Title:** Effect of Two Different Doses of Neostigmine on the Gastric Residual Volume and Aspiration in Critically Ill Patients Under Enteral Feeding; a Comparative Controlled Randomized Trial

**NCT ID:** [NCT06687187](https://clinicaltrials.gov/study/NCT06687187)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 3
- **Lead Sponsor:** Zulekha Hospitals
- **Conditions:** Gastric Reflux
- **Start Date:** 2022-12-01
- **Completion Date:** 2024-05-01
- **CT.gov Last Update:** 2024-11-13

## Brief Summary

A study comparing the effect of two doses of neostigmine on the gastric residual volume in critically ill patients on enteral feeding.

## Detailed Description

Participants were categorized into three groups: Group I and Group II received neostigmine 1 mg and 2 mg, respectively, and a control group received 10 ml of normal saline. All participants received an intravenous administration of 10 mg of metoclopramide. GRV was measured every 3 hours before enteral feeding. aspiration through nasogastric (NG) or orogastric (OG) tubes was done before the next due bolus of feeding.

## Eligibility

- **Minimum age:** 20 Years
- **Maximum age:** 60 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* patients with a GRV \>120ml
* a normal heart rateExclusion Criteria
* absence of comorbidities such as diabetes and renal failure. exclusion Criteria:
* Patients exhibiting new-onset arrhythmias or heart block
* hypotension (systolic blood pressure less than 60 mmHg)
* experiencing active gastrointestinal bleeding or receiving prokinetic medications 8-12 hours before the intervention
* patients with a history of surgery in the gastrointestinal system in the past two weeks history of extrapyramidal manifestations
* patients with electrolyte imbalance
* pregnant patients,
```

## Arms

- **Group I** — received neostigmine 1 mg
- **Group II** — received neostigmine 2 mg
- **Group III** — received normal saline

## Interventions

- **Neostigmine** (DRUG) — two groups (Group I, n= 41) and (Group II, n= 43) received varying doses of neostigmine (1 mg and 2 mg respectively

## Primary Outcomes

- **The risk of aspiration** _(time frame: december 2022 to may 2024)_ — The risk of aspiration in ICU patients on enteral feeding via vaso-gastric or oro-hastric tubes

## Locations (1)

- Al-Azhar faculty of medicine, Cairo, Egypt

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.al-azhar faculty of medicine|cairo||egypt` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06687187.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06687187*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*